• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

One Drop touts study of digital diabetes management platform, plans to develop sensor

April 28, 2022 By Sean Whooley

One Drop
[Image from One Drop]
One Drop announced today that new peer-reviewed research demonstrates sustained blood glucose reductions with its diabetes platform.

New York-based One Drop presented the clinical health outcomes associated with the long-term use of its digital diabetes offering at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The results demonstrated clinically sustained and statistically significant reductions in average blood glucose beyond six months and one year, reflecting meaningful reductions in estimated A1C.

According to a news release, members using One Drop for at least six months reduced their average blood glucose by 26.5 mg/dL, which translates to a 0.9% reduction in estimated A1C. Members who used One Drop for one year or more experienced a 35.2 mg/dL drop in average blood glucose, decreasing A1C by 1.2%.

The company estimates that its digital health platform improves health outcomes and offers estimated cost savings of $2,450 per person per year.

“Today’s healthcare model is untenable for people with chronic conditions and financially unsustainable for payers and health systems,” One Drop CEO and founder Jeff Dachis said in the release. “At One Drop, we look beyond the break-fix cycle of care and toward continuous, data-driven prevention by building connected medical devices and digital health solutions that proactively help individuals gain insights and inform decision-making in real time. Recent research affirms our precision health approach works.”

One Drop also noted that its future plans include a foray into the continuous health sensing market. The company currently has a proprietary sensor in development for giving members access to real-time health data. That sensor remains subject to regulatory approval.

Filed Under: Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: One Drop

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS